Long-Acting HIV Treatment Benefits Adults with Barriers to Daily Pill Taking and Adolescents with Suppressed HIV NIH-Funded Research Networks Provide Evidence on Cabotegravir and Rilpivirine in Additional Populations

https://www.niaid.nih.gov/news-events/long-acting-hiv-treatment-benefits-adults-barriers-daily-pill-taking-and-adolescents?utm_campaign=+59708639&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=